YENO EVOLUTION GmbH
Hubertus Baumgartner | CEO
YENO - PIONEER IN FUNCTIONAL EPIGENETICS & INTEGRATIVE CELL REGULATION
YENO Awareness BV was founded in Amsterdam in 2014 and is the intellectual and conceptual parent company of YENO. In 2020, it gave rise to YENO Evolution GmbH, based in Vienna, a specialized research and development company in the field of functional epigenetics.
As a leader in functional epigenetics, YENO has achieved a technological breakthrough that heralds a new era in modern medicine. YENO is now considered a leading innovator in this field, not because of its size or international structure, but because of its scientific innovation of extraordinary significance: the use of pure epigenetic signal transduction for the targeted regulation of cell functions.
The “YENO Quantum ONE technology” enables unique, scientifically proven access to the cell nucleus and precisely regulates key epigenetic positions. On this basis, epigenetic medicines (prescription medicines according to §21 AMG) and regulatory therapies have been developed, whose effectiveness has been confirmed by in vitro, in vivo, and observational studies.
Research & Development
SERVICE 01
MEDICAL
CUSTOMIZED SOLUTIONS
Research & Development
SERVICE 02
MEDICAL
DEVICES DEVELOPMENT
Research & Development
SERVICE 03
OWN
REMEDY
DEVELOPMENT
SOME ESSENTIAL GENOS PRODUCTS
GENOS ANXA 11
GENOS IMMUNE PLUS
GENOS FIBROCELL PREMIUM MEN
GENOS FIBROCELL PREMIUM WOMEN
GENOS SUPPORTIVE THERAPY
GENOS BREATHIN THERAPY